Silence Therapeutics plc announced on 2025‑10‑23 that it has completed enrollment of 48 phlebotomy‑dependent polycythemia vera patients in the SANRECO Phase 2 study of divesiran, a first‑in‑class siRNA targeting TMPRSS6. The global, randomized, double‑blind, placebo‑controlled trial is designed to evaluate two dosing intervals—every six weeks and every twelve weeks—over a 36‑week core period followed by extension phases.
The primary endpoint of the study is the proportion of patients who maintain hematocrit levels below 45% without phlebotomies between weeks 18 and 36. A responder is defined as a patient with hematocrit <45% in the absence of phlebotomies during this period, addressing a critical unmet need in polycythemia vera management.
Silence expects topline results from the SANRECO Phase 2 study in the third quarter of 2026. Completion of enrollment positions the company to advance regulatory submissions and to demonstrate the clinical benefit of divesiran’s durable, infrequent dosing profile, potentially establishing a new therapeutic standard for polycythemia vera.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.